DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors
Who Have Losses In Excess of $100,000 From Investment In Endo International plc To Contact The Firm
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Endo International
plc (Nasdaq: ENDP) (“Endo” or the “Company”) securities during the period between March 2, 2015 and May 6, 2016, inclusive (the
“Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until
July 25, 2016 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from
investment in Endo securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure
to disclose during the Class Period, with respect to the migraine therapy Frova, that Endo’s arrangements with pharmacy benefit
managers (“PBMs”) included questionable incentives intended to increase sales revenues and Endo’s revenues and revenue projections
relied in part on unsustainable arrangements.
According to the complaint, following a May 5, 2016 filing of the Company’s Form 8-K and issuance of a press release reporting a
loss of $0.40 per diluted share, cutting its 2016 guidance, and announcing changes to its board and management structure and a May
6, 2016 Form 10-Q filing reiterating the financial and operating results, the value of Endo shares declined significantly.
If you have suffered a loss from investment in Endo securities purchased on or after March 2, 2015 and held through the
revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and
your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting
Brower Piven either by email at hoffman@browerpiven.com or by telephone
at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in
question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a
member of the class.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20160615006472r1&sid=mstr2&distro=nx&lang=en)
Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160615006472/en/